Reig Jofre submits press release on the results of the first quarter of 2024

REIG JOFRE’s revenues grow 10% and its EBITDA rises 11% in the first quarter

REIG JOFRE exceeded 86 million euros in sales, 10% higher than the first quarter of 2023. Profitability was also improved, with EBITDA growing by 11% to 10.3 million euros, compared to 9.2 million euros at the close of the same period of the previous year.

The Speciality Pharmacare division, focused on prescription medical products, achieved the highest revenue growth of +26%. The division with the greatest weight in sales, Pharmaceutical Technologies, dedicated to injectable products and antibiotics, achieved a growth of 6%, followed by Consumer Healthcare, the consumer products division, which contributes 24% of the group’s sales, with FORTÉ PHARMA brand, in the French, Belgian and Spanish markets, and REIG JOFRE OTC products.

Download the full document (PDF)